<DOC>
	<DOCNO>NCT02040233</DOCNO>
	<brief_summary>This study investigate safety , tolerability early effect cardiac function partial A1 agonist BAY1067197 patient chronic heart failure . BAY1067197 apply daily 7 day addition standard therapy include beta-blocker . The aim study assess 7 day treatment BAY1067197 well tolerate give top standard therapy heart failure . Furthermore , study aim assess cardiac function improve early course therapy .</brief_summary>
	<brief_title>Multiple Dose Study Heart Failure BAY 1067197</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Adenosine A1 Receptor Agonists</mesh_term>
	<criteria>Clinical diagnosis chronic systolic heart failure ischemic nonischemic etiology : ( New York Heart Association ) NYHA class IIII treatment standard pharmacological therapy treatment systolic heart failure include βblocker ≥ 4 week prior randomization Left ventricular ejection fraction ≤ 40 % : imaging technique within last 3 month accept screening purpose verify baseline CMR ( Cardiac Magnetic Resonance Tomography ) Sinus rhythm least 4 week prior randomization No plan change heart failure relate drug therapy duration study drug treatment Substantial dysfunctional viable myocardium demonstrate baseline CMR : Based standard 17segment model ( AHA American Heart Association ) , 3 segment require demonstration dysfunction ( define visible assessment perform investigator ) viability ( define &lt; 25 % segment area scar burden patient CAD ( Coronary Artery Disease ) ( i.e . zero ) scar burden patient without CAD [ idiopathic CM patient ] ) Men confirm postmenopausal woman woman without childbearing potential . Age : 18 75 year ( inclusive ) first screen visit . Body Mass Index ( BMI ) : /equal 18.0 below/equal 34.9kg/m² Atrial fibrillation / atrial flutter within last 4 week prior randomization currently persistent/permanent atrial fibrillation / atrial flutter Primary valvular disease ( severe valvular disease ) plan valve repair replacement Nonidiopathic nonischemic cause cardiomyopathy ( constrictive , restrictive , hypertrophic cardiomyopathy ; acute myocarditis ) Listing heart transplantation and/or anticipated/implanted ventricular assist device Clinically relevant ventricular arrhythmia within last 2 month ( sustain ventricular tachycardia , ventricular flutter fibrillation ) , base either medical history ICDtesting result ( applicable ) Unstable cardiac condition , indicate requirement IV drug ( diuretic , inotrope , etc . ) NYHA IV within 4 week prior randomization Coronary revascularization within 4 week prior randomization revascularization anticipate need Current permanent intermittent AVBlock &gt; I° history AVBlock &gt; I° within six month enrollment PR duration ≥ 300 m Acute Coronary Syndrome ( define unstable angina [ UA ] , nonST elevation myocardial infarction [ NSTEMI ] , ST elevation myocardial infarction [ STEMI ] ) within 2 month prior randomization Subjects untreated hyperthyroidism hypothyroidism nonstable thyroid function ( intake stable thyroid hormone substitution allow )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>